The disclosure provides an antigenic peptide targeting the extracellular, but not the intracellular, form of CETP to reduce the level of LDL (including oxLDL and other derivatives of LDL) and increase the level of HDL. Accordingly, the disclosure provides a CETP vaccine to overcome the low immunogenicity of CETP and for long-term inhibition of CETP activity to prevent or treat oxLDL or other LDL derivative-related diseases/symptoms.
